centanafadine SR (EB-1020) / Otsuka 
Welcome,         Profile    Billing    Logout  

6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
centanafadine SR (EB-1020) / Otsuka
NCT05257265: A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

Completed
3
459
US
Centanafadine Hydrochloride, Centanafadine QD XR, Placebo, Matching Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-Deficit/Hyperactivity Disorder
09/23
10/23
NCT05428033: A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

Recruiting
3
570
US
centanafadine capsule, centanafadine, centanafadine XR, EB-1020, placebo capsule, placebo comparator, matching placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit/Hyperactivity Disorder
10/25
10/25
NCT05279313: A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

Recruiting
3
700
US
Centanafadine Hydrochloride, Centanafadine, Centanafadine XR, EB-1020
Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit/Hyperactivity Disorder
11/24
11/24
NCT05066724: Efficacy of Centanafadine SR as a Potential Smoking Cessation Treatment

Completed
2
50
US
Centanafadine
Otsuka Pharmaceutical Development & Commercialization, Inc.
Smoking Cessation
05/22
05/22
JUNIPER, NCT05536414: Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

Recruiting
2
336
US
Centanafadine, Escitalopram, Placebo
Otsuka Pharmaceutical Development & Commercialization, Inc.
Major Depressive Disorder
01/25
01/25
NCT04786730: A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder

Completed
1b
50
US
Centanafadine
Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention-deficit Hyperactivity Disorder
04/23
04/23

Download Options